Jinhe Biotechnology 金河生物
34 significant filings since 31 May 2026: 1 on share pledge, 15 on share issue and 9 on equity incentive, and 6 other kinds. The latest, on 24 Sep 2026: 关于回购注销部分限制性股票及注销公司回购专用证券账户库存股减少注册资本暨通知债权人的公告.
自 31 May 2026 起有 34 份重大公告：share pledge 1 份、share issue 15 份、equity incentive 9 份，另有 6 类。最新一份（24 Sep 2026）：关于回购注销部分限制性股票及注销公司回购专用证券账户库存股减少注册资本暨通知债权人的公告。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
No broker has changed its rating on this company in the reports held.
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 西南证券 | 胡光怿 | Unrated | 9 Aug 2026 | 1 | — |
| 中邮证券 | 王琦 | Buy 买入 | 7 May 2026 | 1 | — |
| 太平洋 | 李忠华,程晓东 | Buy 买入 | 11 Nov 2025 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 3 reports. 每行为该券商近十二个月的最新研报；3 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。